391 related articles for article (PubMed ID: 7600453)
1. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
2. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
3. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats.
Yuen VG; Vera E; Battell ML; Li WM; McNeill JH
Diabetes Res Clin Pract; 1999 Jan; 43(1):9-19. PubMed ID: 10199584
[TBL] [Abstract][Full Text] [Related]
4. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats.
Reul BA; Amin SS; Buchet JP; Ongemba LN; Crans DC; Brichard SM
Br J Pharmacol; 1999 Jan; 126(2):467-77. PubMed ID: 10077240
[TBL] [Abstract][Full Text] [Related]
5. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; Thompson KH; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):270-6. PubMed ID: 8402391
[TBL] [Abstract][Full Text] [Related]
6. [Hypoglycemic effects of bis(maltolato)oxovanadium administered by different routes upon diabetic rats].
Zhong XY; Zhang H; Zhang X; Lv WL; Zhang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 36(3):313-8. PubMed ID: 15205708
[TBL] [Abstract][Full Text] [Related]
7. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
9. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
10. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
11. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
12. Increased potency of vanadium using organic ligands.
McNeill JH; Yuen VG; Dai S; Orvig C
Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):175-80. PubMed ID: 8927036
[TBL] [Abstract][Full Text] [Related]
13. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
14. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
Yuen VG; Orvig C; McNeill JH
Am J Physiol; 1997 Jan; 272(1 Pt 1):E30-5. PubMed ID: 9038848
[TBL] [Abstract][Full Text] [Related]
15. Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats.
Cam MC; Faun J; McNeill JH
Metabolism; 1995 Mar; 44(3):332-9. PubMed ID: 7885278
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis and comparison of uptake, distribution, and excretion of 48V-labeled compounds in rats.
Setyawati IA; Thompson KH; Yuen VG; Sun Y; Battell M; Lyster DM; Vo C; Ruth TJ; Zeisler S; McNeill JH; Orvig C
J Appl Physiol (1985); 1998 Feb; 84(2):569-75. PubMed ID: 9475867
[TBL] [Abstract][Full Text] [Related]
18. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats.
Bhanot S; Bryer-Ash M; Cheung A; McNeill JH
Diabetes; 1994 Jul; 43(7):857-61. PubMed ID: 8013747
[TBL] [Abstract][Full Text] [Related]
19. Improvement of impaired glucose tolerance by oral administration of vanadyl sulfate by gavage in streptozotocin-induced diabetic rats.
Tsunajima T; Tatsuki R; Satoh K; Yamamoto A; Hoshi K; Ichihara K
Res Commun Mol Pathol Pharmacol; 1997 Nov; 98(2):190-200. PubMed ID: 9467827
[TBL] [Abstract][Full Text] [Related]
20. In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes.
Cam MC; Cros GH; Serrano JJ; Lazaro R; McNeill JH
Diabetes Res Clin Pract; 1993 May; 20(2):111-21. PubMed ID: 8375263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
